Allergy vaccine - Acambis

Drug Profile

Allergy vaccine - Acambis

Alternative Names: Antiallergy vaccine - Acambis

Latest Information Update: 23 Jul 1999

Price : $50

At a glance

  • Originator University of Birmingham
  • Class Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Food hypersensitivity; Seasonal allergic rhinitis

Most Recent Events

  • 23 Jul 1999 Discontinued-I for Seasonal allergic rhinitis in Poland (Unknown route)
  • 23 Jul 1999 Discontinued-II for Food allergy in Poland (Unknown route)
  • 26 Feb 1998 Phase-II clinical trials for Food allergy in Poland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top